Zacks Research Weighs in on Prestige Consumer Healthcare Inc.’s FY2024 Earnings (NYSE:PBH)

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities research analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a report issued on Monday, April 22nd. Zacks Research analyst R. Department now anticipates that the company will earn $4.33 per share for the year, up from their previous forecast of $4.32. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.33 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q4 2024 earnings at $1.14 EPS, Q4 2026 earnings at $1.20 EPS and FY2026 earnings at $4.75 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 8th. The company reported $1.06 EPS for the quarter, beating the consensus estimate of $1.04 by $0.02. The firm had revenue of $282.74 million during the quarter, compared to the consensus estimate of $280.25 million. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $1.04 earnings per share.

Other equities research analysts have also issued reports about the stock. TheStreet raised shares of Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research note on Monday, February 12th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. One equities research analyst has rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $110.00.

Prestige Consumer Healthcare Stock Down 1.5 %

Shares of PBH opened at $70.13 on Tuesday. The stock’s 50-day moving average price is $70.88 and its two-hundred day moving average price is $64.08. Prestige Consumer Healthcare has a 12 month low of $55.96 and a 12 month high of $75.31. The company has a market capitalization of $3.48 billion, a PE ratio of -42.76, a PEG ratio of 1.89 and a beta of 0.52. The company has a current ratio of 3.09, a quick ratio of 1.92 and a debt-to-equity ratio of 0.75.

Insiders Place Their Bets

In related news, SVP Mary Beth Fritz sold 5,336 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the sale, the senior vice president now directly owns 15,934 shares of the company’s stock, valued at approximately $1,099,446. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds have recently bought and sold shares of PBH. Vanguard Group Inc. raised its position in Prestige Consumer Healthcare by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,756,138 shares of the company’s stock worth $352,391,000 after acquiring an additional 63,375 shares during the period. Ariel Investments LLC lifted its stake in Prestige Consumer Healthcare by 173.8% in the third quarter. Ariel Investments LLC now owns 2,534,786 shares of the company’s stock valued at $144,964,000 after purchasing an additional 1,609,044 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Prestige Consumer Healthcare by 0.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,101,504 shares of the company’s stock valued at $62,995,000 after purchasing an additional 8,661 shares during the period. Allspring Global Investments Holdings LLC increased its position in Prestige Consumer Healthcare by 19.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,087,821 shares of the company’s stock worth $62,213,000 after buying an additional 174,416 shares during the last quarter. Finally, Congress Asset Management Co. MA raised its stake in shares of Prestige Consumer Healthcare by 12.5% in the first quarter. Congress Asset Management Co. MA now owns 764,013 shares of the company’s stock valued at $55,437,000 after buying an additional 84,757 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.